SynOx Therapeutics
PrivateLast Round
Series B
Extension
Oct 30, 2024
Total Funding Raised
$135.7M
Momentum
Top 50%
of companies Caplight tracks
Company Overview
SynOx Therapeutics operates in Healthcare & Life Sciences and is based in Dublin. Its latest recorded funding round was a Series B Extension round in October 2024.
SynOx Therapeutics is a biotechnology company developing emactuzumab, a monoclonal antibody, for the treatment of Tenosynovial Giant Cell Tumour (TGCT) and other macrophage-driven disorders.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Clinical Trials
Business Model
B2B
Customer Profile
Hardware Sales
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
SynOx Therapeutics Comparables
Compare SynOx Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| AmMax Bio Inc. | 81% | |
| Abbisko Therapeutics | 81% | |
| Ono Pharmaceutical Co., Ltd. | 78% |
For institutional investors. Book with your work email.
SynOx Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B Extension | Oct 30, 2024 | ||||
| Series B | Apr 22, 2024 | ||||
| Series A | Nov 19, 2020 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
SynOx Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Forbion | Series B Extension, Series A, Series B |
| Gimv | Series A |
| Gilde Healthcare | Series B Extension |
| HealthCap | Series B Extension, Series B, Series A |
| Bioqube Ventures | Series B Extension, Series B |
| Medicxi | Series A |
Market signals
Structured signals derived from secondary market and firmographic data.
- Aug 22, 2026
Monthly visitors increased 377% MoM, reaching 2.7K.
- May 16, 2026
Monthly visitors grew 86% MoM, from 753 to 1.4K.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- attends_eventNov 10, 2026
On Oct 24th '26, SynOx Therapeutics Ltd presents positive Phase III TANGENT clinical trial findings for emactuzumab at the ESMO 2026 Congress.
For institutional investors. Book with your work email.
SynOx Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about SynOx Therapeutics's valuation, stock price, and market status.
Is SynOx Therapeutics a public or private company?
SynOx Therapeutics is a private company.
What is the current stock price of SynOx Therapeutics?
SynOx Therapeutics is a private company, so its shares have no public market price. Caplight tracks SynOx Therapeutics's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is SynOx Therapeutics worth (valuation)?
Valuation information for SynOx Therapeutics is not publicly available.
Can I buy SynOx Therapeutics stock?
SynOx Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was SynOx Therapeutics's last funding round?
SynOx Therapeutics's most recent funding round was Series B Extension on October 30, 2024.
Who are the main investors in SynOx Therapeutics?
Key investors in SynOx Therapeutics include Forbion, Gilde Healthcare, HealthCap, Bioqube Ventures, Medicxi.
Will SynOx Therapeutics IPO soon?
No public IPO plans have been announced for SynOx Therapeutics.
How can I track SynOx Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades in SynOx Therapeutics's shares on secondary markets.